The phase 3 study of Sputnik V will be conducted on 1500 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.
Earlier, the Data and Safety Monitoring Board reviewed the safety data from the phase 2 clinical trial of the vaccine and recommended the phase 3 recruitment.
In its report, the DSMB concluded that no safety concerns were identified and the study met the primary endpoints of safety.
In September 2020, Dr. Reddy's partnered with Russian Direct Investment Fund to conduct the clinical trials of the Sputnik V vaccine and for its distribution rights in India.
Sputnik V developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world's first registered vaccine against COVID-19 based on the established human adenoviral vector platform.
The vaccine's efficacy is confirmed at 91.4% based on data analysis of the final control point of clinical trials in Russia.
Currently, the vaccine's clinical trials are underway in the UAE, Egypt, Venezuela and Belarus while it has been registered in Algeria, Argentina, Belarus, Bolivia and Serbia for inoculation.
Hong Kong expands COVID-19 vaccine programme to cover teachers, taxi drivers and delivery workers
South Korea finds no link found between COVID-19 vaccine and recent deaths
Seqirus's FLUCELVAX QUADRIVALENT granted US FDA Expanded Age Indication
Moderna to supply the Philippines with 13 million doses of its COVID-19 vaccine
New Zealand to buy additional doses of Pfizer's COVID-19 vaccines to cover whole population
ConserV Bioscience collaborates with eTheRNA immunotherapies NV
Takeda seeks regulatory approval in Japan for Moderna COVID-19 vaccine
Padilla's survey shows companies should create their own COVID-19 vaccine policy
Publix expands COVID‑19 vaccination eligibility for upcoming appointments in Florida